AIMab 7195 / Xencor, Nestle - LARVOL DELTA

Aimmune Therapeutics Announces Second Quarter 2020 Financial Results and Provides Recent Operational Highlights (Aimmune Therapeutics Press Release) - "The POSEIDON (ARC005) phase 3 clinical trial to explore the efficacy and safety of PALFORZIA in young peanut-allergic children ages 1 to <4 years is ongoing. Enrollment has resumed....The Company continues its development of AIMab7195...to explore the potential path to remission in patients with food allergies.The Company expects to file an IND in the first quarter of 2021."

Enrollment status • IND • Allergy • Food Hypersensitivity • Immunology

Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195 (clinicaltrials.gov) - P1; N=57; Active, not recruiting; Sponsor: Xencor, Inc.; Recruiting ➔ Active, not recruiting

Enrollment closed • Biosimilar • Eczema